Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy

A new era of early cancer detection with blood test may change cancer screening paradigms

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update

Lasofoxifene shows promise for women with ESR1-mutated mBC

Scientists discover mechanism of action and an actionable inflammatory axis for air pollution induced NSCLC

Bladder cancer: Current state and future directions in treatment

Optimum treatment algorithm in management of advanced prostate cancer